Anika Thx Q3 2026 rev +10% on growth across Commercial and OEM channels
Anika Therapeutics reported 10% year-over-year revenue growth totaling $30.6 million in Q3 2026, driven by strength in its Senior Commercial and OEM channels, and raised its full-year revenue guidance to account for the results and improved Hyvisc economics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed